| HOME >> BIOLOGY >> TECHNOLOGY |
2008 2007
(a) In order to provide investors and
management a basis to evaluate the
performance of the ongoing operations,
adjusted earnings exclude the impact of
discontinued operations Accounted for
as discontinued operations $- $(1)
(b) Net results from operations expected
to be divested, net of minority interest
Other revenue $(5) $(5)
Less:
Cost of sales (5) (4)
Selling, general and administrative (1) (1)
Total $1 $-
To adjust for the results of
operations of our non-core DDD&I
business which is expected to be
divested. The Company believes
adjusting GAAP earnings for this
loss will allow investors to better
assess our ongoing activities.
(c) Amortization and inventory step up
adjustments:
Cost of sales $(44) $(72)
(d) Incremental PLIVA Depreciation
due to purchase accounting write up
of fixed assets:
Cost of sales $(6) $(4)
Selling, general and
administrative (1) (1)
Total $(7) $(5)
(e) Write off of acquired IPR&D
associated with additional PLIVA
shares $- $(2)
(f) Product Royalty contingency $(1) $-
(g) Litigation Reserve $(1) $(7)
(h) Adjustments to tax expens
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |